Venova Medical
Venova Medical has developed the Velocity™ Percutaneous Arteriovenous Fistula (pAVF) System, a minimally invasive technology that creates arteriovenous fistulas for hemodialysis access with rapid maturation and minimal need for reintervention. This system addresses the high reliance on catheters for dialysis, which are associated with increased morbidity and mortality, by enabling patients to initiate treatment with a functional AVF more efficiently.
- Healthcare Technology
Funding
Raised to date
$17.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many hemodialysis patients initiate treatment using catheters, which are associated with increased morbidity and mortality compared to arteriovenous fistulas (AVFs). Traditional surgical AVF creation often requires extended maturation times and is prone to stenosis, leading to reliance on catheters and suboptimal patient outcomes.
Solution
Venova Medical's Velocity™ Percutaneous Arteriovenous Fistula (pAVF) System offers a minimally invasive solution for creating AVFs for hemodialysis access. The system aims to streamline the AVF creation process, reduce the need for reinterventions, and enable faster maturation, allowing patients to initiate dialysis with a functional AVF more efficiently. By addressing the limitations of surgical AVFs and reducing catheter dependence, the Velocity™ pAVF System seeks to improve vascular access outcomes and lower healthcare costs. The VENOS-1 clinical study demonstrated 100% technical success and rapid maturation, with all subjects achieving physiologic maturation within 6 weeks.
Target Audience
The primary target audience includes patients with chronic kidney disease requiring hemodialysis and healthcare providers specializing in vascular access and nephrology.
Features
- Minimally invasive percutaneous procedure for AVF creation
- Designed to reduce stenosis at the artery-vein junction
- Streamlines the process to create functional dialysis access without follow-up interventions
- Demonstrated rapid maturation in clinical studies (VENOS-1)